{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T04:08:16Z","timestamp":1751083696377,"version":"3.41.0"},"reference-count":61,"publisher":"Media Sphere Publishing House","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["S.S. Korsakov J. Neuro. Psych."],"published-print":{"date-parts":[[2025,6,27]]},"abstract":"<jats:p>Due to the increase in life expectancy of the population, the proportion of people with cognitive impairment (CI) is also increasing. Today, it is known that cardiovascular diseases (CVD) are a significant risk factor for the development of CI. At the same time, the main substrate of CVD, including cerebrovascular events, is atherosclerosis. Statins are one of the most studied classes of drugs in the prevention of CVD. Atorvastatin (Liprimar) is one of the most studied and most frequently prescribed statins that has proven its effectiveness and safety in patients with a wide range of cardiovascular pathology. CI, in turn, lead to a decrease in functional autonomy, ability to work and adherence to treatment, thereby closing the vicious circle. Thus, therapy for CI should be initiated as early as possible, since they are a progressive disorder that eventually transforms into dementia. One of the drugs that has been used for 50 years for symptomatic therapy of CI, including dementia, chronic cerebrovascular and organic brain damage, is nicergoline (Sermion).<\/jats:p>","DOI":"10.17116\/jnevro202512506199","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T16:43:39Z","timestamp":1751042619000},"page":"99","source":"Crossref","is-referenced-by-count":0,"title":["Features of care of patients with cardiovascular diseases and cognitive disorders"],"prefix":"10.17116","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1316-7654","authenticated-orcid":false,"given":"S.V.","family":"Litvinova","sequence":"first","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5801-3742","authenticated-orcid":false,"given":"A.I.","family":"Kochetkov","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0795-8225","authenticated-orcid":false,"given":"O.D.","family":"Ostroumova","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education","place":["Moscow, Russia"]},{"name":"I.M. Sechenov First Moscow State Medical University (Sechenov University)","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro202512506199-1","doi-asserted-by":"publisher","DOI":"10.1596\/978-0-8213-8220-2"},{"key":"key-10.17116\/jnevro202512506199-2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(21)00249-8"},{"key":"key-10.17116\/jnevro202512506199-3","doi-asserted-by":"publisher","DOI":"10.3390\/psychiatryint2020015"},{"key":"key-10.17116\/jnevro202512506199-4","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2015.164"},{"key":"key-10.17116\/jnevro202512506199-5","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000172914.08967.dc"},{"key":"key-10.17116\/jnevro202512506199-6","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000270242.03536.D3"},{"key":"key-10.17116\/jnevro202512506199-7","doi-asserted-by":"publisher","DOI":"10.1179\/016164106X130470"},{"key":"key-10.17116\/jnevro202512506199-8","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.01.030"},{"key":"key-10.17116\/jnevro202512506199-9","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000034176.07159.f8"},{"key":"key-10.17116\/jnevro202512506199-10","unstructured":"Levin OS. Diagnosis and treatment of dementia in clinical practice. M.: MEDpress-inform. 2018 248. (In Russ.)"},{"key":"key-10.17116\/jnevro202512506199-11","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.119.311908"},{"key":"key-10.17116\/jnevro202512506199-12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.06.3061"},{"key":"key-10.17116\/jnevro202512506199-13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30442-3"},{"key":"key-10.17116\/jnevro202512506199-14","doi-asserted-by":"publisher","DOI":"10.15829\/1560-4071-2023-5471"},{"key":"key-10.17116\/jnevro202512506199-15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004816.pub5"},{"key":"key-10.17116\/jnevro202512506199-16","doi-asserted-by":"publisher","DOI":"10.14412\/2074-2711-2019-3-110-115"},{"key":"key-10.17116\/jnevro202512506199-17","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.647990"},{"key":"key-10.17116\/jnevro202512506199-18","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-018-0110-3"},{"key":"key-10.17116\/jnevro202512506199-19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24248-8"},{"key":"key-10.17116\/jnevro202512506199-20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011304"},{"key":"key-10.17116\/jnevro202512506199-21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.09.040"},{"key":"key-10.17116\/jnevro202512506199-22","unstructured":"Gogolashvili NG. Atorvastatin or rosuvastatin? Select from the perspective of evidence-based medicine. Kardiologia. 2012;51(7):84-92. (In Russ.)"},{"key":"key-10.17116\/jnevro202512506199-23","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2013.01.2620"},{"key":"key-10.17116\/jnevro202512506199-24","doi-asserted-by":"crossref","unstructured":"Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesteroleamia by atorvastatin, a new HMG-Ko-A reductase inhibitor. Arteriosclerosis Thromb Vascular Biology. 1995;15:678-682","DOI":"10.1161\/01.ATV.15.5.678"},{"key":"key-10.17116\/jnevro202512506199-25","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(97)00965-x"},{"key":"key-10.17116\/jnevro202512506199-26","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(01)00799-9"},{"key":"key-10.17116\/jnevro202512506199-27","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(01)02337-2"},{"key":"key-10.17116\/jnevro202512506199-28","unstructured":"Jones PH, McKenney JM, Karalis DG. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patientswith dyslipidemia. Evide BasedCardiovascMed. 2005;9(2):98-101"},{"key":"key-10.17116\/jnevro202512506199-29","doi-asserted-by":"publisher","DOI":"10.1177\/107424849800300204"},{"key":"key-10.17116\/jnevro202512506199-30","doi-asserted-by":"publisher","DOI":"10.1515\/jpem.2009.22.1.65"},{"key":"key-10.17116\/jnevro202512506199-31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061894"},{"key":"key-10.17116\/jnevro202512506199-32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.07.053"},{"key":"key-10.17116\/jnevro202512506199-33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16895-5"},{"key":"key-10.17116\/jnevro202512506199-34","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125000787"},{"key":"key-10.17116\/jnevro202512506199-35","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125003421"},{"key":"key-10.17116\/jnevro202512506199-36","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2003.09.031"},{"key":"key-10.17116\/jnevro202512506199-37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050461"},{"key":"key-10.17116\/jnevro202512506199-38","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S135785"},{"key":"key-10.17116\/jnevro202512506199-39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31357-5"},{"key":"key-10.17116\/jnevro202512506199-40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"key-10.17116\/jnevro202512506199-41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2003.12.010"},{"key":"key-10.17116\/jnevro202512506199-42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.08.060"},{"key":"key-10.17116\/jnevro202512506199-43","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-4-201208210-00007"},{"key":"key-10.17116\/jnevro202512506199-44","unstructured":"Gogolashvili NG. Safety issues of atorvastatin usage in patients with a chronic kidney disease. Journal of Aterosclerosis and dyslipidamias. 2016;24(3):15-30. (In Russ.)"},{"key":"key-10.17116\/jnevro202512506199-45","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.03.022"},{"key":"key-10.17116\/jnevro202512506199-46","unstructured":"Instructions for medical use of the drug Liprimar\u00ae \u041b\u041f-\u2116(002230)-(\u0420\u0413-RU). Accessed 22.04.2025. (In Russ.). https:\/\/grls.rosminzdrav.ru\/Grls_View_v2.aspx?routingGuid=04cb144c-9631-46f8-9302-9aa3d84fa887"},{"key":"key-10.17116\/jnevro202512506199-47","doi-asserted-by":"publisher","DOI":"10.15829\/1560-4071-2014-8-7-37"},{"key":"key-10.17116\/jnevro202512506199-48","unstructured":"RLS Rosuvastatin (Rosuvastatin). Accessed 22.04.2025. (In Russ.). https:\/\/www.rlsnet.ru\/drugs\/rozuvastatin-41738"},{"key":"key-10.17116\/jnevro202512506199-49","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200828090-00001"},{"key":"key-10.17116\/jnevro202512506199-50","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/610103"},{"key":"key-10.17116\/jnevro202512506199-51","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20211211036"},{"key":"key-10.17116\/jnevro202512506199-52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003159"},{"key":"key-10.17116\/jnevro202512506199-53","unstructured":"Minfeng H, Xiu R, Shenglong G, et al. A Meta analysis on nicergoline in the treatment of cognitive impairment. J Shanxi Med Univ. 2017;5:479-484"},{"key":"key-10.17116\/jnevro202512506199-54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005090"},{"key":"key-10.17116\/jnevro202512506199-55","unstructured":"Boulu P. Effects du Sermion\u00ae sur les troubles mn.esiques et les fonctions de la vie de relation. Tempo Med. 1990;397:24-27"},{"key":"key-10.17116\/jnevro202512506199-56","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(99)80446-5"},{"key":"key-10.17116\/jnevro202512506199-57","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.1999.630313.x"},{"key":"key-10.17116\/jnevro202512506199-58","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2016.3162"},{"key":"key-10.17116\/jnevro202512506199-59","unstructured":"Bernini FP, Muras I, Maglione F, Smaltino F. Action of nicergoline on the cerebral circulatory insufficiency due to arteriosclerosis. Clinical and angioserographic evaluation. Farmaco Prat. 1977;32(1):32-46. (In Ital.)"},{"key":"key-10.17116\/jnevro202512506199-60","unstructured":"Pilotti A, Monti AM, Colombo E. Therapeutic efficacy of nicergoline in the treatment of patients with cerebral arteriosclerosis. Gaz Med It. 1974;133:293-299. (In Ital.)"},{"key":"key-10.17116\/jnevro202512506199-61","doi-asserted-by":"publisher","DOI":"10.33667\/2078-5631-2020-19-11-18"}],"container-title":["S.S. Korsakov Journal of Neurology and Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T16:43:59Z","timestamp":1751042639000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova\/2025\/6\/1199772982025061099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,27]]}},"alternative-id":["10.17116\/jnevro202512506199"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202512506199","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}